OptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ET
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions, has announced its upcoming second quarter 2024 conference call. The call is scheduled for August 8, 2024, at 4:30 p.m. Eastern Time. Financial results for the quarter ended June 30, 2024, will be released prior to the call. The company's management will host the call, followed by a Q&A session.
Investors and interested parties can join the call using the provided toll-free and international numbers, or access the webcast via the given link. A replay of the call will be available for 12 months through the Investors section of OptimizeRx's website.
OptimizeRx Corp. (Nasdaq: OPRX), un importante fornitore di soluzioni tecnologiche per la salute, ha annunciato la sua prossima conference call per il secondo trimestre del 2024. La chiamata è programmata per l'8 agosto 2024, alle 16:30 ora orientale. I risultati finanziari per il trimestre terminato il 30 giugno 2024 saranno pubblicati prima della chiamata. La gestione dell'azienda guiderà la chiamata, seguita da una sessione di domande e risposte.
Gli investitori e le parti interessate possono partecipare alla chiamata utilizzando i numeri verdi e internazionali forniti, oppure accedere al webcast tramite il link dato. Una registrazione della chiamata sarà disponibile per 12 mesi nella sezione Investitori del sito web di OptimizeRx.
OptimizeRx Corp. (Nasdaq: OPRX), un proveedor líder de soluciones tecnológicas en salud, ha anunciado su próxima conferencia telefónica del segundo trimestre de 2024. La llamada está programada para el 8 de agosto de 2024 a las 4:30 p.m. hora del este. Los resultados financieros del trimestre que finalizó el 30 de junio de 2024 se publicarán antes de la llamada. La dirección de la empresa dirigirá la llamada, seguida de una sesión de preguntas y respuestas.
Los inversores y partes interesadas pueden unirse a la llamada utilizando los números de acceso gratuito e internacionales proporcionados, o acceder al webcast a través del enlace dado. Se dispondrá de una grabación de la llamada durante 12 meses en la sección de Inversores del sitio web de OptimizeRx.
OptimizeRx Corp. (Nasdaq: OPRX)는 선도적인 건강 관리 기술 솔루션 제공업체로서 2024년 2분기 컨퍼런스 콜을 발표했습니다. 콜은 2024년 8월 8일 동부 표준시 기준 오후 4시 30분에 예정되어 있습니다. 2024년 6월 30일에 종료된 분기의 재무 결과는 콜 전에 발표될 것입니다. 회사의 경영진이 콜을 주최한 후, Q&A 세션이 이어집니다.
투자자와 관심 있는 측은 제공된 수신자 부담 및 국제 전화번호를 사용하거나 주어진 링크를 통해 웹캐스트에 접속할 수 있습니다. 콜의 재생은 OptimizeRx 웹사이트의 투자자 섹션에서 12개월 동안 이용 가능합니다.
OptimizeRx Corp. (Nasdaq: OPRX), un fournisseur leader de solutions technologiques en santé, a annoncé sa prochaine conférence téléphonique pour le deuxième trimestre 2024. L'appel est prévu pour le 8 août 2024 à 16h30, heure de l'Est. Les résultats financiers pour le trimestre se terminant le 30 juin 2024 seront publiés avant l'appel. La direction de l'entreprise animera l'appel, suivi d'une session de questions-réponses.
Les investisseurs et les parties intéressées peuvent participer à l'appel en utilisant les numéros gratuits et internationaux fournis, ou accéder au webinaire via le lien donné. Un enregistrement de l'appel sera disponible pendant 12 mois dans la section Investisseurs du site web d'OptimizeRx.
OptimizeRx Corp. (Nasdaq: OPRX), ein führender Anbieter von Gesundheitstechnologielösungen, hat seinen bevorstehenden Konferenzanruf für das zweite Quartal 2024 angekündigt. Der Anruf ist für den 8. August 2024 um 16:30 Uhr Eastern Time geplant. Die finanziellen Ergebnisse für das am 30. Juni 2024 endende Quartal werden vor dem Anruf veröffentlicht. Das Management des Unternehmens wird den Anruf leiten, gefolgt von einer Fragerunde.
Investoren und interessierte Parteien können sich mit den bereitgestellten kostenfreien und internationalen Nummern an dem Anruf beteiligen oder über den angegebenen Link auf das Webcast zugreifen. Eine Wiederholung des Anrufs wird für 12 Monate über den Bereich Investoren auf der Webseite von OptimizeRx verfügbar sein.
- None.
- None.
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call.
OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below:
| Date: | Thursday, August 8, 2024 |
| Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
| Toll Free: | 1-800-343-4849 |
| International: | 1-203-518-9848 |
| Conference ID: | OPRXQ2 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1679004&tp_key=4b22d66114 |
Please call the conference telephone number or log on to the web access link five minutes prior to the start time.
A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at http://www.optimizerx.com/investors.
About OptimizeRx
OptimizeRx provides trailblazing technology that fosters care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the healthcare journey. With the ability to synchronize messaging across 2 million healthcare providers and over 240 million adults across a multitude of digital channels including a proprietary point-of-care network, OptimizeRx is changing the way life sciences engages with customers.
For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s preliminary and unaudited financial results. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
OptimizeRx Contact
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
FAQ
When is OptimizeRx's Q2 2024 earnings call scheduled?
How can investors access OptimizeRx's Q2 2024 earnings call?
What is OptimizeRx's stock symbol?
Where can investors find a replay of OptimizeRx's Q2 2024 earnings call?
